Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Personalized vs. Precision Medicine

Posted on February 3rd, 2017 by in Pharma R&D

Last year was a year of impetus for precision medicine. Former President Obama’s budget for the 2016 fiscal year included $215 million for the National Institutes of Health (NIH), Continue reading “Personalized vs. Precision Medicine” »

The Success of Personalized Anti-Cancer Therapies

Posted on January 4th, 2017 by in Pharma R&D

Every day, thousands of cancer patients face difficult choices about their treatment options. For those affected by advanced, stage 4 cancer, the decisions can be particularly painful. Continue reading “The Success of Personalized Anti-Cancer Therapies” »

Medicine Non-adherence: Time for a Personalized Healthcare Approach?

Posted on December 19th, 2016 by in Pharma R&D

It was interesting to note the article from Beth Snyder Bulik (1) that patient non-adherence to taking their prescribed medicines not only has a potential impact on their health and wellbeing, it also impacts the companies’ and healthcare providers’ bottom lines. Continue reading “Medicine Non-adherence: Time for a Personalized Healthcare Approach?” »

More Drugs, Fewer Patients: Limits of Precision Medicine

Posted on November 9th, 2015 by in Chemistry

A number of targeted medications that are highly effective for a subgroup of patients with a particular disease have emerged in the last decade. These are often needed alternatives to debilitating therapies with uncertain outcomes. The small number of patients that benefit from such therapies, however, may pose a serious challenge looking into the future. Continue reading “More Drugs, Fewer Patients: Limits of Precision Medicine” »